Biogem, a new important contribution to oncology scientific research

Biogem, a new important contribution to oncology scientific research

04 January 2019 -

Nature Medicine published the results of a research carried out by Biogem titled "The molecular landscape of glioma in patients with Neurofibromatosis 1" a common tumor predisposition syndrome in which glioma is one of the prevalent tumors

The research shows that the predisposing germline mutation of the NF1 gene was frequently converted to homozygosity and the somatic mutational load of NF1-glioma was influenced by age and grade. High-grade tumors harbored genetic alterations of TP53 and CDKN2A, frequent mutations of ATRX associated with Alternative Lengthening of Telomere, and were enriched in genetic alterations of transcription/chromatin regulation and PI3 kinase pathways. Low-grade tumors exhibited fewer mutations that were over-represented in genes of the MAP kinase pathway. Approximately 50% of low-grade NF1-gliomas displayed an immune signature, T lymphocyte infiltrates, and increased neo-antigen load. DNA methylation assigned NF1-glioma to LGm6, a poorly defined Isocitrate Dehydrogenase 1 wild-type subgroup enriched with ATRX mutations. 
Thus, the profiling of NF1-glioma defined a distinct landscape that recapitulates a subset of sporadic tumors. 

A new important italian contribution to oncology scientific research

More info: http://www.biogem.it/

 

Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it